OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

A number of other research firms have also recently weighed in on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on shares of OncoCyte in a research report on Monday, April 15th. Stephens reaffirmed an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, OncoCyte has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Price Performance

Shares of NASDAQ OCX opened at $2.48 on Wednesday. OncoCyte has a 52-week low of $2.08 and a 52-week high of $6.20. The business has a 50-day moving average price of $2.89 and a 200 day moving average price of $3.03.

Insider Transactions at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Andrew Arno acquired 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. In the last three months, insiders acquired 2,457,288 shares of company stock valued at $7,176,400. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.